Exelon Corporation Common Stock vs Liquidia Corporation Common Stock — how do they compare? Exelon Corporation Common Stock trades at $43.15 (market cap $43.89B), while Liquidia Corporation Common Stock trades at $33.9 (market cap $3.04B). The key difference: Exelon Corporation Common Stock is far larger — about 14.4× Liquidia Corporation Common Stock's market cap, and Exelon Corporation Common Stock pays a 3.94% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EXC | LQDA | |
|---|---|---|
Market Cap | $43.89B | $3.04B |
Volume | 7,093,882 | 21,111,778 |
Sector | Utilities | Health |
52-Week High | $50.29 | $91.03 |
52-Week Low | $40.20 | $22.02 |
Enterprise Value | $94.75B | $2.94B |
Dividend Yield | 3.94% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
Exelon (EXC) trades at $42.34, up 0.52% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong earnings beats in recent quarters except for a Q2 2026 miss, with Q3 2026 results expected on October 30, 2026. Financials show solid profitability with a 10.99% net income margin and a P/E of 15.56, while cash flow trends indicate improving operational performance.
The outlook is cautiously optimistic, supported by a $48.11 analyst consensus price target and institutional accumulation, but risks include regulatory approvals for dividends and high RSI levels suggesting overbought conditions. Earnings growth and grid investment plans are key catalysts, though investor sentiment remains divided amid rate environment uncertainties.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →